The ITGA2 Knockout SK-HEP-1 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-HEP-1 human liver adenocarcinoma line, featuring targeted disruption of the ITGA2 gene. This heterogeneous batch of edited cells is generated through CRISPR/Cas9-mediated gene disruption, yielding a mixture of loss-of-function variants that collectively eliminate functional integrin alpha2 subunit expression. The polyclonal format is well-suited for pooled population studies where clonal variation is minimized and bulk cellular phenotypes are assessed, without the need for single-cell clonal isolation or characterization. Researchers can employ this model to investigate the consequences of abrogating ITGA2-dependent signaling in a liver cancer context, enabling robust and reproducible experiments across multiple vials from the same editing event.
The host SK-HEP-1 cell line is an ascites-derived hepatic adenocarcinoma model established from a patient with liver adenocarcinoma. These cells exhibit an epithelial morphology and retain key characteristics of liver-derived tumors, including the expression of certain hepatocyte markers and the capacity for anchorage-independent growth. Frequently employed in cancer biology research, SK-HEP-1 cells serve as a well-characterized platform for exploring hepatocellular carcinoma progression, metastasis, and drug responses. Their origin from a metastatic site makes them particularly relevant for studying invasive and migratory properties, which are intimately linked to integrin-mediated adhesion and signaling. In the present knockout model, the SK-HEP-1 background provides a clinically pertinent cellular environment for dissecting the role of ITGA2 in liver cancer pathophysiology.
ITGA2 encodes the alpha2 integrin subunit, which forms the alpha2beta1 heterodimer when complexed with ITGB1. This integrin receptor primarily binds to collagen and laminin within the extracellular matrix, initiating intracellular signals that regulate adhesion, migration, proliferation, and survival. The engagement of ITGA2 triggers the activation of downstream effectors including focal adhesion kinase (FAK) and Src, which in turn phosphorylate and scaffold proteins such as paxillin and talin. Subsequent signaling cascades involve PI3K, Akt, ERK1/2, p38 MAPK, and Rho family GTPases (RhoA, Rac1, Cdc42), coordinating cytoskeletal reorganization and transcriptional responses. Upstream regulators such as TGF-beta, EGF, HGF, SP1, and AP-1 modulate ITGA2 expression, while adaptor proteins kindlin and vinculin reinforce the integrin-actin linkage. Disruption of ITGA2 thus leads to a widespread collapse of these adhesion-dependent pathways, impairing cellular responses to collagen-rich microenvironments.
Within the SK-HEP-1 liver adenocarcinoma context, ITGA2 knockout profoundly attenuates the malignant potential of these cells. Since alpha2beta1 integrin is frequently upregulated in hepatocellular carcinoma and contributes to tumor cell dissemination and survival signals, its removal creates a valuable loss-of-function model for dissecting metastatic mechanisms. The abrogated signaling through FAK-Src and MAPK routes reduces the migratory and invasive capacity of SK-HEP-1 cells, mimicking therapeutic targeting of integrin-mediated pathways. This model also aids in understanding the role of ITGA2 in liver fibrosis, where integrin-collagen interactions drive stellate cell activation. Furthermore, the knockout cell population serves as a critical tool for evaluating the specificity of pharmacological agents directed against integrin alpha2 or its downstream kinases, ensuring that observed effects are genuinely on-target.
Typical research applications leverage this ITGA2 knockout polyclonal population for a variety of functional assays. It is ideal for investigating integrin-mediated signaling in liver cancer through phospho-protein analysis, including FAK and ERK1/2 phosphorylation. Cell adhesion assays on collagen-coated surfaces, wound healing migration assays, and transwell invasion assays quantitatively demonstrate the impact of ITGA2 loss on cell-matrix interactions and motility. Drug target validation studies can incorporate proliferation and viability assays to assess anti-metastatic compounds. Molecular characterization via Western blotting and RT-qPCR confirms the absence of ITGA2 protein and mRNA, while flow cytometry verifies the surface deficiency of integrin alpha2. This knockout model thus provides a comprehensive platform for preclinical research into integrin biology and liver cancer therapeutics. For further details or technical support, please contact Ascent Research.
